BUDAPEST, Hungary & BOSTON, February 14, 2013 /PRNewswire/ -- Leading pharmaceutical company continues the trend of building future cheminformatics platforms on ChemAxon technology ChemAxon, a leader in providing chemistry software solutions and consulting services for life science research, announces that Boehringer Ingelheim has chosen its chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners. ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate. ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap. ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D. With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year. Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, "The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems." To discover more about how ChemAxon's leading edge cross-platform solutions power modern cheminformatics and chemical communication, please visit http://www.chemaxon.comAbout ChemAxonChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America. SOURCE ChemAxon Ltd.